Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Saint Priest En Jarez – page 61

1 694 clinical trials in Saint Priest En Jarez, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Saint Priest En Jarez at a glance
1 694
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 694 trials in Saint Priest En Jarez

Open in trial search

Chondrosarcoma+2

Not yet recruiting

Phase I/II Study of Dinutuximab Beta, Irinotecan, and Sirolimus in Children, Adolescents, and Adults with Relapsed or Refractory Bone Sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Dinutuximab Beta
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Rituximab versus azathioprine for remission maintenance in patients with primary angiitis of the central nervous system – randomized controlled trial

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Azathioprine
  • Sponsor:Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience

Systemic scleroderma

Not yet recruiting

Safety and efficacy of obinutuzumab in patients with active diffuse systemic sclerosis: a randomized, double-blind, placebo-controlled trial

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Lichen sclerosus

Not yet recruiting

A Phase 3 Study of Delgocitinib Cream to Evaluate Efficacy and Safety in Adult Women with Lichen Sclerosus

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Delgocitinib
  • Sponsor:Leo Pharma A/S

Palliative care

Not yet recruiting

Efficacy and Safety of Transmucosal Midazolam for Proportional Palliative Sedation in Children with Refractory Symptoms

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Dobutamine Hydrochloride
  • Sponsor:Centre Leon Berard

Obinutuzumab in patients with pure class V lupus nephritis (systemic lupus erythematosus membranous nephropathy) – phase II trial

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Endometrial cancer+6

Not yet recruiting

Phase 2 Study of Lirafugratinib in Patients with Previously Treated Unresectable Advanced Solid Tumors with FGFR2 Fusion (Excluding Cholangiocarcinoma)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lirafugratinib hydrochloride
  • Sponsor:Elevar Therapeutics Inc.

Immunogenicity and safety of RSV A/B prefusion F protein vaccine versus RSV F glycoprotein recombinant adjuvanted vaccine in lung and stem cell transplant recipients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:GSKVx000000017064
  • Sponsor:Hospices Civils De Lyon

Cystic fibrosis

Not yet recruiting

Effect of Stopping Long‑Term Azithromycin in Stable Non‑Cystic Fibrosis Bronchiectasis Patients: A Randomized Controlled Trial

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azithromycin
  • Sponsor:Centre Hospitalier Intercommunal Creteil

Appendicitis

Not yet recruiting

Patient‑chosen treatment vs routine surgery for adult uncomplicated acute appendicitis: trial of amoxicillin‑clavulanic acid versus appendectomy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin Sodium
  • Sponsor:Assistance Publique Hopitaux De Paris

Non-small cell lung cancer

Not yet recruiting

Phase 3 Study of Taletrectinib as Adjuvant Therapy in Patients with Completely Resected ROS1‑Positive Stage IB‑IIIA Non‑Small Cell Lung Cancer

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Taletrectinib
  • Sponsor:Nuvation Bio Inc.

Colitis ulcerative

Not yet recruiting

Safety and efficacy of stopping versus maintenance dose of filgotinib, tofacitinib and upadacitinib in adult ulcerative colitis patients in deep remission

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Filgotinib
  • Sponsor:Assistance Publique Hopitaux De Marseille

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Saint Priest En Jarez

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on head and neck cancer, multiple myeloma, and acute myeloid leukemia. Studies evaluating novel therapeutic approaches including targeted treatments and combination therapies.

  • Head & Neck Squamous Cell Carcinoma
  • Multiple Myeloma Treatment
  • Pancreatic Adenocarcinoma

Investigating breakthrough treatments and improving patient outcomes through innovative therapeutic strategies.

02 Autoimmune Disorders

Comprehensive research into inflammatory conditions and autoimmune diseases, with particular focus on Crohn's disease, rheumatoid arthritis, and novel treatment approaches.

  • Psoriatic Arthritis
  • Ulcerative Colitis
  • Sjögren's Syndrome

Evaluating advanced therapies and treatment combinations to improve disease management and patient quality of life.

03 Cardiovascular & Pulmonary Studies

Innovative research in pulmonary arterial hypertension and related conditions, exploring new therapeutic options and treatment strategies.

  • Pulmonary Hypertension
  • Chronic Kidney Disease
  • Cardiovascular Complications

Testing novel compounds and therapeutic approaches to address complex cardiovascular and pulmonary conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.